ArrePath
Dylan Morris is a Managing Director at Insight. He joined the firm in 2021 to focus on investments in computational biology. Dylan was previously a general partner at CRV, where he built the bioengineering practice, leading the firm’s investments in Dyno Therapeutics, Recursion Pharmaceuticals, and Plexium, among others. Prior to CRV, Dylan invested at Innovation Endeavors, Eric Schmidt’s early stage venture capital firm, where he drove investments in companies operating at the intersection of data science and life science.
Before becoming an investor, Dylan cofounded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Prior to that, he conducted graduate research in biochemistry and molecular biophysics at Caltech, where he co-authored multiple peer-reviewed publications. Dylan received his A.B. in Computer Science from Harvard University.
This person is not in the org chart
This person is not in any offices
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.